Reference health
Potential Pharmacokinetic Drug‐Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain
108/108 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 108 checked references that resolve
resolves10.5455/njppp.2015.5.2005201557
Drug interaction and its implication in clinical practice and personalized medicine
resolves10.3390/pharmaceutics10030106
Beneficial Pharmacokinetic Drug Interactions: A Tool to Improve the Bioavailability of Poorly Permeable Drugs
resolves10.1016/j.jpain.2015.07.009
Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data
resolves10.1177/1179544120906461
Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
resolves10.1186/s42238-020-00024-2
Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019)
resolves10.1002/14651858.cd012182.pub2
Cannabis-based medicines for chronic neuropathic pain in adults
resolves10.1016/j.archoralbio.2019.05.028
Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain
resolves10.1016/j.lfs.2011.05.018
Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes
resolves10.1124/dmd.109.026898
Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids
resolves10.1089/can.2015.0012
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy
resolves10.1016/j.lfs.2006.12.032
Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes
resolves10.2174/1871527316666170413104516
Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
resolves10.3109/03602532.2013.849268
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review
resolves10.1016/j.lfs.2011.02.017
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: Role of phenolic hydroxyl groups in the resorcinol moiety
resolves10.1124/dmd.111.041384
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
resolves10.1177/0897190019828920
The Potential Clinical Implications and Importance of Drug Interactions Between Anticancer Agents and Cannabidiol in Patients With Cancer
resolves10.3390/jcm8070989
Potential Adverse Drug Events and Drug–Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
resolves10.1097/JCP.0000000000001089
The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications
resolves10.1080/14740338.2017.1397128
Drug-drug interactions as a result of co-administering Δ<sup>9</sup>-THC and CBD with other psychotropic agents
resolves10.1016/j.ajog.2013.08.005
Cannabidiol enhances xenobiotic permeability through the human placental barrier by direct inhibition of breast cancer resistance protein: an ex vivo study
resolves10.1038/sj.bjp.0707467
The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoids
resolves10.1016/j.bcp.2005.12.033
The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells
resolves10.1124/jpet.105.098541
Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
resolves10.7717/peerj.2081
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice
resolves10.1111/epi.13060
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
resolves10.1002/cpdd.665
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
resolves10.1542/peds.2019-3256
Clinically Significant Drug-Drug Interaction Between Methadone and Cannabidiol
resolves10.1111/ajt.15398
Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
resolves10.1007/s00204-018-2244-6
Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects
resolves10.1038/clpt.1990.2
Morphine and metabolite behavior after different routes of morphine administration: Demonstration of the importance of the active metabolite morphine-6-glucuronide
resolves10.1124/dmd.32.4.447
QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES
resolves10.1016/j.clpt.2006.01.009
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
resolves10.1016/j.drugalcdep.2014.11.031
Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study
resolves10.1097/AJP.0000000000000364
The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain
resolves10.1089/can.2017.0012
Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report
resolves10.1038/s41386-018-0011-2
Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability
resolves10.2174/1570159X15666170504095823
Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
resolves10.2174/156802611795371288
Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
resolves10.3390/pharmaceutics10040192
Modulation of Opioid Transport at the Blood-Brain Barrier by Altered ATP-Binding Cassette (ABC) Transporter Expression and Activity
resolves10.1097/00000542-200005000-00030
Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein
resolves10.1002/jps.20893
Oxycodone induces overexpression of P‐glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats
resolves10.1211/0022357022782
Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat
resolves10.1007/s00213-003-1718-1
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood?brain barrier of Abcb1a gene knockout mice
resolves10.1111/j.1742-7843.2009.00428.x
Uptake/Efflux Transport of Tramadol Enantiomers and<i>O</i>‐Desmethyl‐Tramadol: Focus on<i>P</i>‐Glycoprotein
resolves10.1097/ADM.0000000000000118
Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly With Intravenous Fentanyl in Humans
resolves10.1159/000374090
Acetaminophen: Dose-Dependent Drug Hepatotoxicity and Acute Liver Failure in Patients
resolves10.1093/toxsci/kfi211
Phenobarbital and Phenytoin Increased Acetaminophen Hepatotoxicity Due to Inhibition of UDP-Glucuronosyltransferases in Cultured Human Hepatocytes
resolves10.1111/j.1365-2125.2011.03911.x
Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors
resolves10.3390/molecules24122256
Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration
resolves10.1111/j.1365-2710.2006.00763.x
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
resolves10.1258/acb.2009.009003
Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity
resolves10.1016/j.forsciint.2012.12.020
A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine
resolves10.3109/15563650.2011.626421
Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms
resolves10.1002/cpt.597
Clinical pharmacogenetics implementation consortium guideline (CPIC) for <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and dosing of tricyclic antidepressants: 2016 update
resolves10.1007/s40262-015-0310-2
Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain
resolves10.1097/00000446-200701000-00022
SSRIs AND THE SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION
resolves10.2169/internalmedicine.2346-18
Acute Hyponatremia Resulting from Duloxetine-induced Syndrome of Inappropriate Antidiuretic Hormone Secretion
resolves10.2165/11589340-000000000-00000
Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function
resolves10.1111/j.1365-2125.2008.03098.x
Serotonin transporter polymorphism and bleeding time during SSRI therapy
resolves10.1016/j.cgh.2014.06.021
Use of Selective Serotonin Reuptake Inhibitors and Risk of Upper Gastrointestinal Bleeding: A Systematic Review and Meta-analysis
resolves10.1016/j.ijcard.2005.03.065
QT interval prolongation associated with venlafaxine administration
resolves10.2165/11536200-000000000-00000
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
resolves10.1016/j.jphs.2016.01.002
P-glycoprotein inhibitors improve effective dose and time of pregabalin to inhibit intermittent cold stress-induced central pain
resolves10.1016/S1474-4422(03)00409-5
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs
resolves10.1002/14651858.CD009183.pub2
Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults
resolves10.1111/j.1528-1157.1993.tb02419.x
Valproate (VPA) Metabolites in Various Clinical Conditions of Probable VPA‐Associated Hepatotoxicity
resolves10.1016/S0006-2952(03)00076-5
The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases
resolves10.1016/S0022-3476(82)80320-X
Carnitine deficiency and hyperammonemia associated with valproic acid therapy
resolves10.2174/1381612811319380012
Concentration-Dependent Mechanisms of Adverse Drug Reactions in Epilepsy
resolves10.1155/2016/2920108
Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of Ammonia
resolves10.3390/molecules24091694
Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model
resolves10.1016/S0140-6736(18)30136-3
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial
resolves10.1124/jpet.106.102491
Valproic Acid Is Not a Substrate for P-glycoprotein or Multidrug Resistance Proteins 1 and 2 in a Number of in Vitro and in Vivo Transport Assays
resolves10.1124/dmd.106.009340
IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION
resolves10.1016/j.tox.2003.09.004
Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests
resolves10.1016/j.jocn.2015.01.016
Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999–2014
resolves10.1007/BF03191157
Lamotrigine and valproate pharmacokinetics interactions in epileptic patients
resolves10.1155/2018/5371854
Lamotrigine-Valproic Acid Interaction Leading to Stevens–Johnson Syndrome
resolves10.1016/j.neuropharm.2015.01.015
The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2)
The 7 references without a DOI — listed, not checked
no DOI — not checkedOpioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ′atypical′ opioid analgesic
no DOI — not checkedThe glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)
no DOI — not checkedExpression of drug pump protein MRP2 in lipopolysaccharide-treated rats and its impact on the disposition of acetaminophen
no DOI — not checkedAntidepressants for chronic pain
no DOI — not checkedCardiovascular considerations in antidepressant therapy: an evidence-based review
no DOI — not checkedStevens–Johnson syndrome associated with concomitant use of lamotrigine and valproic acid
no DOI — not checkedPharmacology and drug interactions of cannabinoids
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1155/2020/3902740"><img src="https://citestamp.com/citestamped/10.1155/2020/3902740/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1155/2020/3902740)